Coherus BioSciences Completes Acquisition of Surface Oncology
Coherus BioSciences (CHRS) said Friday it has completed the acquisition of Surface Oncology (SURF). Upon closing, Coherus issued 0.1960 of its common shares at $5.2831 apiece for every Surface common
Coherus Completes Surface Oncology Acquisition
REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the closing of the previously announced acquisition of Surface Oncology, Inc. (Surface or Surface Oncology), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment.
Surface Oncology Says Takeover by Coherus BioSciences Gets Backing From ISS, Glass Lewis
Surface Oncology (SURF) said independent proxy advisors Institutional Shareholder Services and Glass Lewis recommended stockholders vote in favor of the buyout by Coherus BioSciences (CHRS). If Surfac
Surface Oncology Announces ISS And Glass Lewis Both Recommend Stockholders Vote "FOR" The Proposed Merger With Coherus BioSciences >SURF
Surface Oncology Announces ISS And Glass Lewis Both Recommend Stockholders Vote "FOR" The Proposed Merger With Coherus BioSciences >SURF
Surface Oncology GAAP EPS of -$0.46
Surface Oncology Q2 EPS $(0.46) Misses $(0.34) Estimate
Surface Oncology (NASDAQ:SURF) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.34) by 35.29 percent. This is unchanged from the same period last year.
Surface Oncology: If Coherus Merger Isn't Approved by Shareholders, Cash Runway Extends Through 2023 >SURF
Surface Oncology: If Coherus Merger Isn't Approved by Shareholders, Cash Runway Extends Through 2023 >SURF
Press Release: Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023 CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immun
Surface Oncology 2Q Loss/Shr 46c >SURF
Surface Oncology 2Q Loss/Shr 46c >SURF
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2023.
Downgrade Aside, Cathie Wood Buys $1.2M Worth Of SoFi Shares
On Thursday, Cathie Wood-led Ark Invest made a significant purchase of SoFi Technologies Inc (NASDAQ:SOFI) shares, amidst a volatile market environment for the company. This move comes in the wake of
Cathie Wood Sells $7M Tesla Stock Friday Amid Pullback, Bets Big On This Crypto-Linked Stock
Cathie Wood's Ark Invest offloaded more Tesla Inc. (NASDAQ:TSLA) shares on Friday even as it amassed this crypto-linked stock for a second straight day.Tesla Selling Spree: Ark, through its Ark Innova
Surface Oncology (SURF) Was Downgraded to a Hold Rating at JonesTrading
Synergy Of Coherus And Surface Oncology: Analyst Forecasts $50M Savings And 2024 Profitability
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on the shares of Coherus BioSciences, Inc. (NASDAQ:CHRS), lowering the price target to $22 from $24. Coherus BioSciences has recentl
Ten Stocks Trending On Discord For Tuesday June 20, 2023: TEVA, BVS, ASB, CLNN, CTG, SURF, DICE, SPY, BABA, TASK
Ten Stocks Trending On Discord For Tuesday June 20, 2023: TEVA, BVS, ASB, CLNN, CTG, SURF, DICE, SPY, BABA, TASK
Wedbush Downgrades Surface Oncology to Neutral From Outperform, Adjusts Price Target to $1.15 From $3
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: Price: 0.81, Change: +0.02,
Benzinga's Top Ratings Upgrades, Downgrades For June 20, 2023
UpgradesTudor Pickering upgraded the previous rating for EQT Corp (NYSE:EQT) from Hold to Buy. EQT earned $1.70 in the first quarter, compared to $0.81 in the year-ago quarter. At the moment, the stoc
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Surface Oncology, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - June 20, 2023) - Rigrodsky Law, P.A. is investigating Surface Oncology, Inc. ("Surface") (NASDAQ: SURF) regarding possible breaches of fiduciary duties and othe
Analysts Conflicted on These Healthcare Names: Calliditas Therapeutics (CALT), Surface Oncology (SURF) and Crinetics Pharmaceuticals (CRNX)
Surface Oncology Cut to Neutral From Buy by HC Wainwright & Co.
Surface Oncology Cut to Neutral From Buy by HC Wainwright & Co.
No Data